FDA Approves ZENBEXUS — E.R. Squibb & Sons, L.L.C.
E.R. Squibb & Sons, L.L.C. received FDA approval for Iberdomide Hydrochloride, a novel oral lenalidomide analog, suggesting a potential for significant expansion of Squibb's market share in the liquid steroids market for multiple myeloma, contingent upon addressing potential safety concerns preceding the 2026 launch.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed